Alkem Laboratories Limited

NSEI:ALKEM Stock Report

Market Cap: ₹648.9b

Alkem Laboratories Balance Sheet Health

Financial Health criteria checks 6/6

Alkem Laboratories has a total shareholder equity of ₹119.1B and total debt of ₹12.4B, which brings its debt-to-equity ratio to 10.4%. Its total assets and total liabilities are ₹171.2B and ₹52.1B respectively. Alkem Laboratories's EBIT is ₹23.1B making its interest coverage ratio -11.6. It has cash and short-term investments of ₹22.9B.

Key information

10.4%

Debt to equity ratio

₹12.36b

Debt

Interest coverage ratio-11.6x
Cash₹22.89b
Equity₹119.10b
Total liabilities₹52.07b
Total assets₹171.17b

Recent financial health updates

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Nov 15
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Sep 24
What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 03
Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13
Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13
Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01
Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22
Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17
Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Dec 27
We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Financial Position Analysis

Short Term Liabilities: ALKEM's short term assets (₹111.1B) exceed its short term liabilities (₹41.8B).

Long Term Liabilities: ALKEM's short term assets (₹111.1B) exceed its long term liabilities (₹10.3B).


Debt to Equity History and Analysis

Debt Level: ALKEM has more cash than its total debt.

Reducing Debt: ALKEM's debt to equity ratio has reduced from 23.5% to 10.4% over the past 5 years.

Debt Coverage: ALKEM's debt is well covered by operating cash flow (158.1%).

Interest Coverage: ALKEM earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 05:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alkem Laboratories Limited is covered by 35 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Shrikant AkolkarAngel Broking Private Limited
null nullAntique Stockbroking Ltd.